The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ADC Therapeutics, Inc. | Common | H0036K147 | 2,658 | 334,384 | SH | SOLE | 334,384 | 0 | 0 | ||
Amicus Therapeutics Inc. | Common | 03152W109 | 5,323 | 495,603 | SH | SOLE | 495,603 | 0 | 0 | ||
Arcutis Biotherapeutics inc | Common | 03969K108 | 5,509 | 258,500 | SH | SOLE | 258,500 | 0 | 0 | ||
Avadel Pharmaceuticals Plc | ADR | 05337M104 | 1,006 | 412,363 | SH | SOLE | 412,363 | 0 | 0 | ||
AVROBIO, Inc. | Common | 05455M100 | 596 | 647,918 | SH | SOLE | 647,918 | 0 | 0 | ||
Biocryst Pharmaceuticals Inc. | Common | 09058V103 | 6,762 | 639,089 | SH | SOLE | 639,089 | 0 | 0 | ||
Black Diamond Therapeutics, Inc. | Common | 09203E105 | 590 | 239,888 | SH | SOLE | 239,888 | 0 | 0 | ||
Crinetics Pharmaceuticals Inc. | Common | 22663K107 | 6,839 | 366,676 | SH | SOLE | 366,676 | 0 | 0 | ||
Cullinan Oncology, Inc. | Common | 230031106 | 98,051 | 7,648,268 | SH | SOLE | 7,648,268 | 0 | 0 | ||
Cytokinetics Inc. | Common | 23282W605 | 7,632 | 194,246 | SH | SOLE | 194,246 | 0 | 0 | ||
Epizyme, Inc. | Common | 29428V104 | 5,035 | 3,425,202 | SH | SOLE | 3,425,202 | 0 | 0 | ||
ESSA Pharma, Inc. | Common | 29668H708 | 2,082 | 660,892 | SH | SOLE | 660,892 | 0 | 0 | ||
G1 Therapeutics, Inc. | Common | 3621LQ109 | 4,233 | 856,798 | SH | SOLE | 856,798 | 0 | 0 | ||
Geron Corporation | Common | 374163103 | 13,074 | 8,434,991 | SH | SOLE | 8,434,991 | 0 | 0 | ||
Harmony Biosciences Hldgs Inc. | Common | 413197104 | 6,707 | 137,517 | SH | SOLE | 137,517 | 0 | 0 | ||
Harpoon Therapeutics, Inc. | Common | 41358P106 | 6,106 | 3,196,707 | SH | SOLE | 3,196,707 | 0 | 0 | ||
Inhibrx, Inc. | Common | 45720L107 | 11,615 | 1,023,325 | SH | SOLE | 1,023,325 | 0 | 0 | ||
Inozyme Pharma Inc. | Common | 45790W108 | 3,172 | 664,980 | SH | SOLE | 664,980 | 0 | 0 | ||
Intellia Therapeutics, Inc. | Common | 45826J105 | 15,497 | 299,409 | SH | SOLE | 299,409 | 0 | 0 | ||
Iovance Biotherapeutics Inc Com | Common | 462260100 | 13,248 | 1,200,000 | SH | SOLE | 1,200,000 | 0 | 0 | ||
iTeos Therapeutics, Inc. | Common | 46565G104 | 35,966 | 1,745,943 | SH | SOLE | 1,745,943 | 0 | 0 | ||
Karuna Therapeutics inc | Common | 48576A100 | 2,530 | 20,000 | SH | SOLE | 20,000 | 0 | 0 | ||
Madrigal Pharmaceuticals inc | Common | 558868105 | 3,221 | 45,000 | SH | SOLE | 45,000 | 0 | 0 | ||
Merus N.V. | Common | N5749R100 | 20,817 | 919,482 | SH | SOLE | 919,482 | 0 | 0 | ||
Mirum Pharmaceuticals Inc. | Common | 604749101 | 5,615 | 288,531 | SH | SOLE | 288,531 | 0 | 0 | ||
Neogenomics Inc. | Common | 64049M209 | 1,105 | 135,573 | SH | SOLE | 135,573 | 0 | 0 | ||
Oncorus, Inc. | Common | 68236R103 | 2,995 | 2,377,031 | SH | SOLE | 2,377,031 | 0 | 0 | ||
Phathom Pharmaceuticals inc | Common | 71722W107 | 1,632 | 193,326 | SH | SOLE | 193,326 | 0 | 0 | ||
Provention Bio Inc | Common | 74374N102 | 2,370 | 592,435 | SH | SOLE | 592,435 | 0 | 0 | ||
Reata Pharmaceuticals inc-a | Common | 75615P103 | 5,470 | 180,000 | SH | SOLE | 180,000 | 0 | 0 | ||
Repare Therapeutics, Inc. | Common | 760273102 | 22,941 | 1,639,849 | SH | SOLE | 1,639,849 | 0 | 0 | ||
Revolution Medicines, Inc. | Common | 76155X100 | 2,846 | 146,041 | SH | SOLE | 146,041 | 0 | 0 | ||
TCR2 Therapeutics, Inc. | Common | 87808K106 | 9,776 | 3,370,982 | SH | SOLE | 3,370,982 | 0 | 0 | ||
Travere Therapeutics Inc. | Common | 89422G107 | 6,735 | 277,950 | SH | SOLE | 277,950 | 0 | 0 | ||
Verastem, Inc. | Common | 92337C104 | 3,764 | 3,244,650 | SH | SOLE | 3,244,650 | 0 | 0 | ||
Werewolf Therapeutics, Inc. | Common | 95075A107 | 9,767 | 2,388,011 | SH | SOLE | 2,388,011 | 0 | 0 | ||
YmAbs Therapeutics, Inc. | Common | 984241109 | 6,713 | 443,702 | SH | SOLE | 443,702 | 0 | 0 |